Kornimate/medical-research-clean huggingface dataset:
the immunogenicity of intradermal influenza vaccination in hemodialysis patients

Conditions: Hemodialysis Patients

Summary: the purpose of this study is to determine whether half-dose intradermal influenza vaccine is as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.

hemodialysis patients are at high risk of influenza infection due to suppress immune status.it is recommended to immunize them against influenza annually.in intradermal vaccination antigens directly present to the large numbers of antigen-presenting cells in the skin and it may cause greater immunogenicity than in the intramuscular method. reduced-dose intradermal influenza vaccine is immunogenic in healthy adult, patients with solid cancer and three groups of immunocompromized patients including rheumatologic patients treated with anti-tnf, hiv-infected and stem cell transplanted patients. in this study we compare the efficacy of influenza vaccines in half dose intradermal and standard intramuscular methods among hemodialysis patients.

Eligibility criteria:
inclusion criteria: * patients under chronic hemodialysis exclusion criteria: * history of flu infection in last month * history of flu vaccination in 2009 * hospitalization in last month * taking immune suppressants drugs * hemodialysis less than twice weekly

Keywords: intradermal influenza vaccine hemodialysis patients
serum level of il31,33 and 36 in egyptian paients with psoriasis

Conditions: Psoriasis

Summary: evaluating serum level of il 31 , il33 and il36 and their correlation with disease activity in patients with psoriasis in assuit university hospital . * to correlate their levels with disease activity using pasi score . * to allow better understanding of the pathophysiological mechanism of the disease .

serum samples will be collected from 45 psoriasis patients and 45 matched healthy individuals. after full history taking and dermatological examination, the disease severity will be assessed using the psoriasis area and severity index (pasi) score. all patients enrolled in our study had no other autoimmune or systemic diseases and underwent no systemic treatment including glucocorticoids, immunosuppressive drugs, or phototherapy at least 1 month before the pasi score evaluation and sample collection period. wriiten informed consent will be obtained from all the patients and healthy controls. assessment of serum interleukin-31 ,33 and 36 concentrations in psoriatic patients patients and controls blood samples will collected from psoriatic patients and controls, and will centrifuged for 15 min at 1000 rpm. next, the serum samples will be subdivided into small aliquots to be stored at -80°c until analysis for cytokine levels. elisa kits will be used to determine serum il-31 , 33 and 36

Eligibility criteria:
inclusion criteria: * patients with all types of psoriasis. * healthy volunteers without a family history of psoriasis or other autoimmune disease. exclusion criteria: * other autoimmune , other chronic inflammatory or systemic diseases. * cases received glucocorticoids, immunosuppressive drugs at least 1 month before sample collection .

Keywords: interleukine 31,33 and 36
access in dialysis for better outcomes in patient therapy

Conditions: Central Venous Catheter; Catheter-Related Bloodstream Infection (CRBSI) Nos

Summary: this is a prospective, multi-center health economic study in canada. participants will be randomly assigned to receive either the study or control dialysis catheter. the primary objective is to evaluate resource utilization in ontario related to hemodialysis catheter placement including tissue plasminogen activator (tpa) usage, catheter exchange rates, catheter patency, and missed dialysis days.


Eligibility criteria:
inclusion criteria: * is indicated for a dialysis catheter for the purpose of attaining long-term vascular access for hemodialysis. long-term vascular access is defined by physician anticipated duration of hemodialysis for three months or longer. * is ≥ 18 years of age. * is indicated to receive dialysis treatment at a location where dialysis treatment data will be accessible by the study team. * is able to comprehend and have signed the informed consent form (icf) to participate in the study. exclusion criteria: * has known or suspected presence of other device-related infection, bacteremia, or septicemia or has been treated with antibiotics for documented or suspected infection within prior 45 days. * is receiving prophylactic anti-coagulation or anti-platelet pharmacotherapy for the purpose of central venous catheter (cvc) patency (anti-coagulation or anti-platelet pharmacotherapy for therapeutic indications do not exclude the patient from the study). * has severe chronic obstructive lung disease. * had past radiation therapy at the prospective insertion site. * had previous episodes of venous thrombosis or vascular surgical procedures at the prospective insertion site. * has local tissue factors that will prevent proper device stabilization and/or access. * has a stent placed in the vessel where the catheter will be placed * is pregnant * history of drug or alcohol abuse in the past 12 months obtained from patient record and/or interview * subjects who weigh ≤ 30 kg. * has been previously enrolled in this clinical study, or is participating in another clinical study that is contraindicative to the treatment or outcomes of this investigation.
subarachnoid or infiltration for hemorrhoidectomy

Conditions: Hemorrhoid

Summary: there will be compared the postoperative analgesic effect of infiltration or spinal block for hemorrhoidectomy

this is a prospective, randomized study, including 40 patients between 18 and 60 years, of both genders, asa 1 or 2. patients in group 1 (n = 20) will be submitted to spinal block and group 2 (n = 20) to infiltration. the spinal block will be performed with 10 mg of 0.5% bupivacaine. the infiltration will be performed with 10 ml of 0.5% bupivacaine with epinephrine on each side. will be evaluated: intensity of pain on a numerical scale from 0 to 10 every 15 minutes, relaxation of the sphincter muscles, intensity of pain after the operation every 30 minutes until reached the criteria for discharge, muscle strength of the lower limbs every 30 minutes, bp, hr, so2, fr, other items that determine the conditions of discharge (urine output, nausea and vomiting), time to hospital discharge, and duration of analgesia. adverse effects and complications will be noted.

Eligibility criteria:
inclusion criteria: * will be included 50 patients, asa physical status 1 or 2 undergoing hemorrhoidectomy after approval by the ethics committee and signed consent form exclusion criteria: * there will be excluded patients with associated diseases (fistula, fissure), infection at the puncture site, using anticoagulants or analgesics (up to 2 weeks before the procedure) and pregnant.

Keywords: infiltration hemorrhoidectomy postoperative pain
mr-linac guided ultra-hypofractionated rt for prostate cancer

Conditions: Prostate Cancer; Radiotherapy Side Effect; Magnetic Resonance-linac; Stereotactic Ablative RT; Adaptive Radiotherapy; Localised Disease; Oligometastatic Disease

Summary: 1. to investigate the tolerability of mr-linac based stereotactic ablative radiotherapy (mrl-sbrt)for patients with localized prostate cancer 2. to assess the acute and late toxicities, efficacy and quality of life for patients treated by mrl-sbrt 3. to simulate the dose planning and assess the feasibility of simultaneous-boost for mr-prominent foci 4. to investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-mri pre-/post-mrl-sbrt, to further ascertain the predictive factors of local persisting and/or relapse disease


Eligibility criteria:
inclusion criteria: * age≥18 years。 * histology confirmed prostate cancer. * risk stratification, localised disease including patients with low-risk(ct1-t2a，psa \<10ng/ml，gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(ct2b-t3a or minimally t3b，psa 10-40ng/ml，gleason score 7-8) disease. * oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical sbrt dose) * ecog 0-2 * postate gland volume ≤100cc * ipss score of \<18 * informed consent: all patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed exclusion criteria: * contraindications to mri. * turp within the past 6 months * ulcerative colitis, crohn's disease, ataxia telangiectasia, or systemic lupus erythematosus * previous pelvic irradiation * refuse contraception
a study of ro7617991 in patients with locally advanced or metastatic mage-a4-positive solid tumors

Conditions: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult

Summary: this study will evaluate the safety, tolerability, and pharmacokinetics of ro7617991, and will make a preliminary assessment of the anti-tumor activity of ro7617991 in human leukocyte antigen (hla)-a\*02 eligible patients with locally advanced or metastatic melanoma-associated antigen a4 (mage-a4)-positive solid tumors.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * body weight ≥40 kilograms * life expectancy of at least 12 weeks * confirmed eligible hla-a\*02 genotype and tumor with confirmed mage-a4 expression * histologically confirmed locally advanced or metastatic solid tumor malignancy that has relapsed or is refractory to established therapies * measurable disease, according to recist v1.1 * adequate hematologic and end-organ function * resolution to grade ≤2 of all acute, clinically significant treatment-related toxicity from prior therapy * an archival tumor tissue specimen or fresh baseline biopsy (when archival is not available) is required exclusion criteria: * pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of ro7617991 or tocilizumab * clinically significant cardiopulmonary dysfunction * clinically significant liver disease * poorly controlled type 2 diabetes mellitus * active hepatitis b or c infection * positive test for human immunodeficiency virus (hiv) * history of allergic reactions to red meat or tick bites or known galactose-alpha-1,3-galactose (alpha-gal) hypersensitivity * symptomatic, untreated, or actively progressing central nervous system (cns) metastases * symptomatic pleural effusion, pericardial effusion, or ascites or any prior procedural intervention for pleural effusion, pericardial effusion, or ascites within 6 weeks prior to enrollment * active or history of autoimmune disease or immune deficiency * treatment with systemic immunosuppressive medications * prior allogeneic stem cell or solid organ transplantation
immunogenicity, safety and tolerability, of chiron meningococcal c conjugate vaccine administered to healthy premature and non premature children of 3 months of age

Conditions: Prevention of Meningococcal Infection

Summary: immunogenicity, safety and tolerability, of chiron meningococcal c conjugate vaccine administered to healthy premature and non premature children of 3 months of age


Eligibility criteria:
inclusion criteria: * healthy children of 11 to 15 weeks of age exclusion criteria: * children who previously received any kind of meningococcal c vaccine, dtap-ipv-hbv-hib vaccine or a hepatitis b vaccine at birth * children who have a previous ascertained or suspected disease caused by n. meningitidis, corynebacterium diphtheriae, clostridium tetani, poliovirus, hepatitis b or h. influenzae type b, culture proven bordetella pertussis, or clinical condition of spasmodic cough for a period longer than or equal to 2 weeks associated with apnea or whooping * children who have had household contact with and/or intimate exposure to an individual with culture proven n. meningitidis serogroup c or bordetella pertussis, within the previous 60 days

Keywords: prevention of meningococcal meningitis meningococcal vaccines conjugate immunology infant
cervical carcinoma in shatby university hospital and its relation to human papilloma virus

Conditions: Cervical Cancer

Summary: incidence of detection of carcinogenic types of human papilloma virus in 60 cases of cervical cancer


Eligibility criteria:
inclusion criteria: * cervical cancer exclusion criteria: * none
the effects of cannabidiol and ∆-9-thc in humans

Conditions: Healthy

Summary: cannabis is the most commonly used illicit substance in the us and herbal cannabis consists of a number of cannabinoids including δ-9 thc and cbd. this study will characterize the interactive effects of the two major components of cannabis i.e. δ-9-thc and cbd.


Eligibility criteria:
inclusion criteria: * exposed to cannabis at least once in lifetime exclusion criteria: * cannabis naive

Keywords: cannabis marijuana cannabidiol cbd thc psychotic disorders
comparison of vortioxetine versus other antidepressants with pregabalin augmentation in burning mouth syndrome

Conditions: Burning Mouth Syndrome

Summary: background: the treatment of burning mouth syndrome (bms) presents a challenge in tailoring appropriate medication for individual patients. antidepressants have demonstrated efficacy in alleviating symptoms in most cases; however, a subset of patients exhibit limited or no response to these treatments. the augmentation with pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving quality of life in chronic pain conditions. this study aimed to compare the efficacy of vortioxetine with other antidepressants (ssris/snris) in combination with pregabalin in a cohort of unresponsive bms patients and to predict treatment response using clinical data. methods: a 52-week randomized, open-label, active-controlled study was conducted, enrolling 203 bms patients previously treated with one antidepressant for 12 weeks and non-responder to the treatment. the study sample have included two groups: group a (136) received vortioxetine, while group b (67) received ssris/snris. pregabalin (75mg/day) was added to both groups, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks. treatment response was assessed by measuring reduction in vas and sf-mpq scores (\>50 or 1-2) and ham-a and ham-d scores (\>50% or ≤7) at 12, 24, 36 and 52 weeks. classical logistic regression with a stepwise algorithm and random forest machine learning models were used to predict treatment response.


Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of bms based on the international classification of orofacial pain, 1st edition \[international classification of orofacial pain, 1st edition (icop) cephalalgia, 2020\] * patients of any race or gender; complaining of oral burning recurring daily for \>2 h per day for \>3 months; * normal blood test findings (including blood count, blood glucose levels, glycated hemoglobin, serum iron, ferritin and transferrin). * bms patients previously treated with one antidepressant for 12 weeks and non-responder to the treatment exclusion criteria: * the presence of any disease that could be recognized as a causative factor of bms, * a history of a psychiatric disorder or a neurological or organic brain disorder, * a history of alcohol or substance abuse, * the presence of obstructive sleep apnea syndrome (osas) * uncontrolled hypertension, diabetes, hiv, narrow-angle glaucoma, or participants enrolled in other investigational studies. * participants requiring continued treatment with medications that adversely interact with the study medications (eg, quinolone antibiotics, warfarin, agents inhibiting serotonin reuptake) or with hereditary problems of fructose intolerance, glucose galactose malabsorption, or sucrose isomaltase insufficiency * pregnancy and lactation were exclusion criteria, and women of childbearing potential were required to receive a highly effective form of contraception.

Keywords: burning mouth syndrome vortioxetine pregabalin drug therapy
observational study with mode of action-analysis of cystorenal cranberry extract in patients with recurrent urinary tract infections

Conditions: Urinary Tract Infections

Summary: the main focus of this observational study is to analyze the possible effects of cranberry dietary supplements on the intestinal microbiota in women with recurrent uncomplicated urinary tract infections. in a secondary analysis the possible influence of the microbiota changes on the recurrence frequency in the follow-up should be analyzed.


Eligibility criteria:
inclusion criteria: • chronic recurrent urinary tract infections (≥3 infections per year or 2 infections in the last 6 months) exclusion criteria: * renal insufficiency (gfr \<60), * anatomical or known structural causes of urinary tract infections * regular consumption of probiotics or probiotic yogurts (at least 5x / week) * intake of antibiotics in the last 4 weeks * intake of marcumar * simultaneous participation in another study
nuevo amanecer: promoting the psychosocial health of latinas

Conditions: Breast Neoplasms; Psychology, Social

Summary: the purpose of this study is to test whether a new program nuevo amanecer (a new dawn), improves the quality of life of latinas diagnosed with breast cancer. trained latina counselors who have had breast cancer provide support to recently diagnosed women. the investigators call these counselors peer support counselors.

this study will assess the effectiveness of a cognitive-behavioral stress management (cbsm) intervention for newly diagnosed latina breast cancer patients. in our prior work, the investigators established the appropriate content of the intervention, the need for early intervention, and the value of culturally competent peer support. in this study the investigators will adapt an evidence-based cbsm intervention designed to meet these needs. this study will use a randomized controlled trial (rct) design with a wait-listed usual care control group to adapt the intervention and test its effectiveness in improving breast cancer specific quality-of-life, and decreasing anxiety and breast cancer specific distress. the new, adapted intervention will be called "nuevo amanecer" (a new dawn).

Eligibility criteria:
inclusion criteria: * self-identifies as latina * diagnosed with stage 0, i, ii, or iii in the prior month * primarily spanish-speaking, or spanish monolingual * aged 18 or older * diagnosed in alameda, contra costa, san mateo, san francisco or santa clara counties, california. exclusion criteria: * previous cancer diagnosis except for non-melanoma skin cancer * terminal illness * stage iv breast cancer (distant metastasis)

Keywords: breast cancer latinas peer support counselor spanish speaking community based
characterization of airway mucus in bronchiectasis patients and healthy controls

Conditions: Bronchiectasis Adult

Summary: analysis of mucus, mucin and dna concentration, muc5b/5ac ratio, rheology, osmotic pressure, cohesion and nucleotides in sputum on 30 individual samples of good quality in healthy individuals and those with bronchiectasis. (60 total)

in this study the investigators will investigate the mucus properties in individuals with idiopathic bronchiectasis and healthy individuals without a history of lung disease. in order to understand how mucus is abnormal in disease conditions, the investigators need to understand the mucus biochemical and biophysical properties in healthy individuals. in this study the investigators will prospectively recruit patients with bronchiectasis and healthy individuals from the community to provide airway sputum samples. in these samples the investigators will measure an array of mucus properties. this will help our understanding of the mucus-obstructive lung diseases and facilitate the development of appropriate and effective disease prevention strategies. a key question is whether mucus is hyper-concentrated and has abnormal biophysical properties in individuals with mucus-obstructive lung disease. to answer this question, the investigators need to understand the properties of the mucus in individuals with idiopathic bronchiectasis and no history of lung disease. this study will allow us to collect airway mucus (sputum) from individuals with bronchiectasis and healthy individuals with no history of lung disease.

Eligibility criteria:
participants who meet all the following criteria are eligible for the study: * written informed consent * bronchiectasis patients: available ct of the chest that shows evidence of dilated airways fulfilling radiographic criteria for bronchiectasis in more than one lobe and chronic cough. participants who meet any of the following criteria will not be eligible for the study: * healthy individuals: a history of lung disease, current asthma symptoms or medication use, premature birth (\<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness, current smoker or a history of smoking tobacco products. * bronchiectasis patients: premature birth (\<37 week gestation), a history of lung disease of infancy, or neurological or cardiovascular illness. * younger than 18 years of age

Keywords: sputum bronchiectasis lung disease
endostapler sleeve gastrectomy study

Conditions: Obesity

Summary: the goal of this prospective, post-market study is to measure aeon™ endostapler performance for laparoscopic sleeve gastrectomy surgery versus the endo gia™ reloads with tri-staple™ technology from medtronic.

stapler performance will be evaluated primarily by incidence and degree of staple line bleeding from endoscopic images, evaluated by a blinded third-party. the study will include 60 total consecutive cases of individuals undergoing a planned laparoscopic sleeve gastrectomy (lsg). the lsg procedure will be performed according to institutional standard-of-care and all subjects will undergo standard preoperative evaluation as well as post-operative care.

Eligibility criteria:
inclusion criteria: * patients undergoing planned laparoscopic sleeve gastrectomy * informed consent for study obtained and signed from each subject exclusion criteria: * planned open surgical approach * use of staple line reinforcement material (buttress) * revision or other bariatric procedure * patients with a bleeding disorder: known coagulopathy, or platelets \ 45sec, or prothrombin time (pt) \>15sec, or international normalized ratio (inr) \>1.5 * patients with active hiv or hepatitis b * patients under the age of 18 on the date of the surgery * patients who are pregnant * patients using tobacco products within the last 2 weeks prior to surgery date * patients using cortisone or related products within the last 2 weeks prior to surgery date